/PROT

PROT Stock - Proteonomix, Inc.

Q: What is the analyst price target for PROT?

Analyst price target information is not currently available for PROT.

Q: What is PROT's market cap?

Market capitalization information is not currently available for PROT.

Healthcare|Biotechnology|OTC

$0.00+0.00%

+$0.00 (+0.00%) • Dec 19

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

BUY

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

100

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+10.0%upside

Target: $0.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for PROT

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2002

FY2008

FY2009

FY2010

FY2011

← Swipe to see more →

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta-54.99

52W High$0.00

52W Low$0.00

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2011	FY2010	FY2009	FY2008	FY2002
Revenue	$26,004	$83,321	$141,647	$132,038	$206,702
Gross Profit	$26,517	$67,471	$118,455	$114,527	$42,413
Gross Margin	102.0%	81.0%	83.6%	86.7%	20.5%
Operating Income	$-1,307,000	$-3,450,000	$-3,819,000	$-4,856,000	$-650,095
Net Income	$-1,384,000	$-3,470,000	$-3,858,000	$-4,969,000	$4.09M
Net Margin	-5322.3%	-4164.6%	-2723.7%	-3763.3%	1977.9%
EPS	$-0.21	$-0.75	$-1.16	$-2.33	$103.70

Company Overview

Proteonomix, Inc., a biotechnology company, focuses on developing therapeutics based upon the use of human cells and their derivatives. The company's products include Proteoderm, an anti-aging skin cream based on a proprietary and patented matrix of proteins that reduce wrinkles; UMK-121, a treatment for liver disease using a combination of two or three approved drugs to mobilize particular bone marrow stem cells; and StromaCel, a treatment for cardiac patients within two weeks of a myocardial infarction using stem cells derived from donor bone marrow and administered through IV solution to repair heart tissue. Its products also comprise NC-138, a proprietary matrix of proteins, which act on the skin to enhance activities that reduce wrinkles. The company was formerly known as National Stem Cell Holding, Inc. and changed its name to Proteonomix, Inc. in August 2008. Proteonomix, Inc. was incorporated in 1995 and is based in Hawthorne, New Jersey.

Visit Website